Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Approves 23 NMEs in 2017, Lowest in Past 5 Years
February 28, 2018
- PMDA to Take Applications for Using MID-NET Starting April 1
February 27, 2018
- Clinical Research Law to Take Effect on April 1
February 26, 2018
- Shionogi’s Single-Dose Flu Med Gets Accelerated OK
February 26, 2018
- Darzalex, Somatuline Grab Orphan Status for New Indications
February 23, 2018
- PMDA Announces Procedures for Using MID-NET
February 21, 2018
- Turning Point for Blood Products? Discussions on Basic Policy on Blood Law Moving Ahead
February 20, 2018
- Chugai Hemophilia Drug, Novel Zoster Vaccine Set for Approval Review on March 2
February 19, 2018
- Nobelpharma’s Sakigake-Designated Sirolimus Gel Up for MHLW Panel Review on March 1
February 19, 2018
- Harvoni Approved for Genotype 2 Hep C, Zytiga for Earlier Line
February 19, 2018
- PhRMA Wants Japan Put on “Priority Watch List” in USTR’s Trade Barrier Report
February 16, 2018
- MHLW OKs Authorized Generics for Aimix, Cravit IV, Takepron; June Listing Eyed
February 16, 2018
- 20 Gx Makers Flock to Aimix, Sawai Earns Approval for Tamiflu Copy for June Listing
February 16, 2018
- MHLW Launches Startup Support Project
February 16, 2018
- MHLW Looked at Balance and Made Major Revision Plans for Drug Pricing: Official
February 14, 2018
- Label Revisions Ordered for Gardenia Fruit Kampo Agents, Stocrin
February 14, 2018
- Japan Cabinet Adopts Bill to Require Generic Use for Welfare Recipients
February 13, 2018
- Payers Give High Marks for “Bold” Pricing Reform, but Not Happy with PMP
February 8, 2018
- Chuikyo Submits Recommendation for FY2018 Reimbursement Policy Reform, Drug Pricing Package Enshrined
February 8, 2018
- MHLW Notifies of Revisions of Ministerial Ordinances to Prevent Distribution of Counterfeit Drugs
February 7, 2018
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…